CD274 and neoplasm: They are proven to be useful when combining immune checkpoint blockade with drugs that stimulate the immune system (e.g., through immunogenic cell death mechanisms) (9), and thus would be more effective than free agents to combat the immunosuppressive TNBC tumor microenvironment and enhance the PD-1/PD-L1 blocking therapy.